The recall involves Veklury for Injection with Lot #47035CFA (NDC # 61958-2901-02) and an expiration date of November 2025. Gilead is voluntarily recalling 1 lot of Veklury ® (remdesivir) for ...
Lugano, Switzerland – June 24, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive ...
Glenmark Pharmaceuticals Inc., USA (Glenmark), a research-led, global pharmaceutical company, announces the launch of vancomycin hydrochloride for injection USP, 750 mg/vial, 1.25 g/vial and 1.5 ...
Gilead Sciences recently announced a voluntary recall of one lot of its Veklury (remdesivir) for injection 100 mg/vial, to the consumer level, after confirming the presence of a glass particle in the ...
The new "F4" formulation is 4 times more concentrated than the version currently available on the market. Theratechnologies announced that the Food and Drug Administration (FDA) has approved Egrifta ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the availability in the United States of Ertapenem for Injection in a 1 gram vial presentation. The new product is the generic ...
Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback